In summary, the results of this study indicate that PKNOX1 is highly expressed in most tumors and is closely related to poor prognosis, tumor immunity and therapy, and tumor proliferation and migration, providing a theoretical basis for the use of PKNOX1 as a pan-cancer prognostic biomarker and a tumor immunity biomarker. This evidence concerns the gene PKNOX1 and cancer.